Is Milizumab available in China? Can it be purchased domestically?

In recent years, with the rapid development of biological agents in the field of treatment of autoimmune diseases, more and more new targeted drugs have become available, bringing more treatment options to patients. Milikizumab (Mirikizumab), as a new anti-IL-23p19 monoclonal antibody, has shown good efficacy and safety in the treatment of moderately to severely active ulcerative colitis and other diseases, and has attracted widespread attention from the global medical community. So, is this drug currently on the market in the country? Can patients purchase it domestically? This article will give you detailed answers.

What is Milizumab?

Mirikizumab (Mirikizumab) is a drug produced by Eli Lilly and Company (Eli The humanized IgG4 monoclonal antibody developed by Lilly mainly targets the p19 subunit of interleukin 23 (IL-23). IL-23 is an important factor that drives the activation of Th17 cells and is involved in the pathogenesis of various inflammatory diseases. By selectively inhibiting the p19 subunit of IL-23, militizumab can effectively control the inflammatory response, thereby alleviating symptoms and delaying disease progression.

Currently, militizumab is mainly used to treat moderately to severely active ulcerative colitis (UC), and has demonstrated significant effects over placebo in multiple clinical studies. After patients use militizumab, common improvements include relief of abdominal pain, reduction in diarrhea frequency, relief of bloody stools, and improvement in quality of life.

How is the domestic listing situation?

As of now (2025year4month), militizumab has not yet been approved by the National Food and Drug Administration (NMPA) in my country, and therefore has not been officially launched in the domestic market. This means that patients cannot directly purchase the drug through formal channels in domestic hospitals or pharmacies, nor can they be reimbursed through medical insurance.

Despite this, some patients seek ways to purchase drugs overseas through international drug purchasing channels or cross-border medical platforms to obtain militizumab treatment options. Although this method alleviates patients' medication needs to a certain extent, it also involves certain compliance and safety risks. Therefore, it is recommended that patients operate with caution under the guidance of professional doctors.

Foreign usage and price information

In European and American countries, militizumab has been approved for the treatment of moderate to severe ulcerative colitis and has accumulated a large amount of clinical data in practical applications. Especially in the European market, militizumab has been widely used, and patients' feedback on its efficacy and tolerability are generally positive.

Regarding price, as a new biological agent, militizumab is priced relatively high. Currently, a box of the European original research version (specification: 300mg/15ml) sells for about more than 10,000 yuan. The specific price fluctuates slightly depending on the country and sales channel. For patients who require long-term maintenance treatment, this cost may pose greater financial pressure.

Is it worth trying?

For patients with moderately to severely active ulcerative colitis who do not respond well to conventional treatments, the emergence of militizumab undoubtedly brings a new treatment possibility. Especially when otherIL-23 targeted drugs (such as ustekinumab, guselkumab) have unsatisfactory efficacy, militizumab is expected to provide a more targeted anti-inflammatory effect.

However, before choosing Militizumab treatment, patients still need to be evaluated by a professional doctor to confirm whether the indications match the individualized treatment plan. In addition, when purchasing drugs overseas, you need to carefully choose formal channels to prevent buying fake or inferior drugs.

Milizumab, a cutting-edgeIL-23p19 inhibitor, shows promise in the treatment of inflammatory bowel diseases such as ulcerative colitis. Although it has not yet been launched in my country, as global clinical data continues to accumulate, it is more likely to enter the Chinese market in the future. Prior to this, if patients needed medication, they could purchase it abroad through compliant channels, but they must do so under the guidance of a doctor.

For patients and family members who are concerned about new drug developments, closely following the approval process of militizumab in my country may bring more hope for future treatment options.

Reference materials:https://omvoh.lilly.com/